254 related articles for article (PubMed ID: 25702193)
1. Hypofractionated stereotactic radiotherapy in combination with bevacizumab or fotemustine for patients with progressive malignant gliomas.
Minniti G; Agolli L; Falco T; Scaringi C; Lanzetta G; Caporello P; Osti MF; Esposito V; Enrici RM
J Neurooncol; 2015 May; 122(3):559-66. PubMed ID: 25702193
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated stereotactic radiotherapy and continuous low-dose temozolomide in patients with recurrent or progressive malignant gliomas.
Minniti G; Scaringi C; De Sanctis V; Lanzetta G; Falco T; Di Stefano D; Esposito V; Enrici RM
J Neurooncol; 2013 Jan; 111(2):187-94. PubMed ID: 23129347
[TBL] [Abstract][Full Text] [Related]
3. Concurrent radiotherapy: fotemustine combination for newly diagnosed malignant glioma patients, a phase II study.
Beauchesne PD; Taillandier L; Bernier V; Carnin C
Cancer Chemother Pharmacol; 2009 Jun; 64(1):171-5. PubMed ID: 19352662
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of stereotactic radiosurgery and adjuvant bevacizumab in patients with recurrent malignant gliomas.
Cuneo KC; Vredenburgh JJ; Sampson JH; Reardon DA; Desjardins A; Peters KB; Friedman HS; Willett CG; Kirkpatrick JP
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):2018-24. PubMed ID: 21489708
[TBL] [Abstract][Full Text] [Related]
5. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
6. GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.
Pérez-Segura P; Manneh R; Ceballos I; García A; Benavides M; Fuster J; Vaz MA; Cano JM; Berros JP; Covela M; Moreno V; Quintanar T; García Bueno JM; Fernández I; Sepúlveda J
Clin Transl Oncol; 2016 Aug; 18(8):805-12. PubMed ID: 26542177
[TBL] [Abstract][Full Text] [Related]
7. Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma.
Shapiro LQ; Beal K; Goenka A; Karimi S; Iwamoto FM; Yamada Y; Zhang Z; Lassman AB; Abrey LE; Gutin PH
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):636-42. PubMed ID: 22765876
[TBL] [Abstract][Full Text] [Related]
8. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
9. An overview of fotemustine in high-grade gliomas: from single agent to association with bevacizumab.
Lombardi G; Farina P; Della Puppa A; Cecchin D; Pambuku A; Bellu L; Zagonel V
Biomed Res Int; 2014; 2014():698542. PubMed ID: 24800248
[TBL] [Abstract][Full Text] [Related]
10. Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse.
Antoni D; Jastaniah Z; Haoming QC; Gaultier C; Ahle G; Couchot J; Atlani D; Schott R; Clavier JB; Srour R; Chaussemy D; Noël G
Cancer Radiother; 2016 Jun; 20(4):282-91. PubMed ID: 27318555
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
[TBL] [Abstract][Full Text] [Related]
12. Role of adjuvant or salvage radiosurgery in the management of unresected residual or progressive glioblastoma multiforme in the pre-bevacizumab era.
Niranjan A; Kano H; Iyer A; Kondziolka D; Flickinger JC; Lunsford LD
J Neurosurg; 2015 Apr; 122(4):757-65. PubMed ID: 25594327
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated Stereotactic Radiotherapy as a Salvage Therapy for Recurrent High-Grade Gliomas: Single-Center Experience.
Reynaud T; Bertaut A; Farah W; Thibouw D; Crehange G; Truc G; Vulquin N
Technol Cancer Res Treat; 2018 Jan; 17():1533033818806498. PubMed ID: 30343637
[TBL] [Abstract][Full Text] [Related]
14. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
16. [Fotemustine (Muphoran) in 22 patients with relapses of high-grade cerebral gliomas].
Malhaire JP; Lucas B; Simon H; Person H; Dam-Hieu P; Labat JP
Bull Cancer; 1999 Mar; 86(3):289-94. PubMed ID: 10210763
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
Guan Y; Xiong J; Pan M; Shi W; Li J; Zhu H; Gong X; Li C; Mei G; Liu X; Pan L; Dai J; Wang Y; Wang E; Wang X
BMC Cancer; 2021 Feb; 21(1):123. PubMed ID: 33546642
[TBL] [Abstract][Full Text] [Related]
18. Irradiation and bevacizumab in high-grade glioma retreatment settings.
Niyazi M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; Geisler J; la Fougère C; Ertl L; Linn J; Siefert A; Belka C
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):67-76. PubMed ID: 21030162
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.
Lee YP; Jung HA; Lee MS; Choi JW; Kong DS; Seol HJ; Nam DH; Lee JI; Lee SH
J Neurooncol; 2022 Feb; 156(3):541-549. PubMed ID: 35094201
[TBL] [Abstract][Full Text] [Related]
20. Treatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylation.
Fabi A; Metro G; Russillo M; Vidiri A; Carapella CM; Maschio M; Cognetti F; Jandolo B; Mirri MA; Sperduti I; Telera S; Carosi M; Pace A
BMC Cancer; 2009 Mar; 9():101. PubMed ID: 19335893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
